Aurinia Pharmaceuticals Inc

AUPH · Moat type: REGULIERUNG

MoatScore

9/10

Fair Value

58 USD

Margin of Safety

+72.4 %

Rating

STARK

Aurinia Pharmaceuticals markets Voclosporin (Lupkynis), an approved calcineurin inhibitor for the treatment of lupus nephritis, and generates revenues almost exclusively through the sale of this prescription specialty pharmaceutical product.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.